Plain-English translation of NCT04585750 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new drug called , which is designed to work against cancers that have a specific genetic change (called a TP53 Y220C mutation). is an oral medication—you take it by mouth as a daily pill. The study is evaluating whether this medication is safe and whether it helps shrink or stop the growth of advanced cancers in people who have this particular genetic mutation.
Many cancers develop because a gene called TP53 stops working properly. When this gene has a specific mutation (Y220C), it loses its ability to fight cancer cells. This medication is designed specifically to reactivate this broken gene, which could help the immune system fight back against the cancer.
You likely qualify if…
You likely don't qualify if…
You will take as a daily oral pill at home. The study has different phases: in earlier phases, researchers determine the safest and most effective dose by starting low and gradually increasing it; in later phases, you'll receive the recommended dose and visit the clinic regularly for blood tests, scans, and check-ups to see how well the medication is working and to monitor for any side effects. Some participants may also receive a second drug called (given as an intravenous infusion every three weeks) alongside .
AI-generated summary from trial data · Aug 15, 2026 · Not medical advice
United States